- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
Repligen Corporation Sees Boost in Institutional Investment
Royce & Associates LP increases stake in biotech company by over 66%
Published on Mar. 2, 2026
Got story updates? Submit your updates here. ›
Royce & Associates LP, a major institutional investor, has significantly increased its position in Repligen Corporation (NASDAQ:RGEN), a biotechnology company headquartered in Waltham, Massachusetts. According to a recent SEC filing, Royce & Associates boosted its stake in Repligen by 66.1% during the third quarter, now owning approximately 0.26% of the company's outstanding shares.
Why it matters
Repligen is a leading provider of critical bioproduction technologies and consumables for the pharmaceutical and biotech industries. The increase in institutional investment from a firm like Royce & Associates suggests growing confidence in Repligen's business model and growth prospects within the broader investment community.
The details
Royce & Associates, a renowned investment management firm, now owns 148,658 shares of Repligen, up from 89,522 shares in the previous quarter. This investment represents approximately $19.9 million in Repligen's stock at the end of the third quarter. The boost in Royce's position comes as Repligen has seen its share price fluctuate between $102.96 and $175.77 over the past 52 weeks, reflecting the volatility in the biotech sector.
- Royce & Associates increased its Repligen stake in the 3rd quarter of 2026.
- Repligen's stock price has ranged between $102.96 and $175.77 over the past 52 weeks.
The players
Royce & Associates LP
A major institutional investment firm that has significantly increased its stake in Repligen Corporation.
Repligen Corporation
A biotechnology company headquartered in Waltham, Massachusetts that provides critical bioproduction technologies and consumables to the pharmaceutical and biotech industries.
The takeaway
The boost in institutional investment from a respected firm like Royce & Associates underscores the market's confidence in Repligen's ability to capitalize on growth opportunities in the biopharmaceutical industry. As Repligen continues to innovate and expand its product portfolio, its stock could remain an attractive option for institutional and retail investors alike.
